Company Overview of Angiogenix, Inc.
Angiogenix, Inc., a biopharmaceutical company, develops therapeutic solutions for chronic vascular disease. Its products include ACCLAIM, a treatment for chronic ischemia; ANGX-1039, a peripheral vascular disease drug therapy for peripheral blood flow; ANGX-3227, a treatment for sickle cell disease; and Vasotrophin, a product for the generation of blood vessels. The company serves cardiovascular disease, peripheral vascular disease, and sickle cell disease markets. Angiogenix, Inc. was founded in 1997 and is headquartered in Burlingame, California.
500 Airport Boulevard
Burlingame, CA 94010
Founded in 1997
Key Executives for Angiogenix, Inc.
Similar Private Companies By Industry
|Merrell Pharmaceuticals, Inc.||United States|
|E. Claiborne Robins Company, Inc.||United States|
|Agensys, Inc.||United States|
|Elucid Bioimaging Inc.||United States|
|InnoZen, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Santa Monica, CA | AstellasPosted: Mar 10
- Princeton, NJ | RGPPosted: Mar 05
- Deerfield, IL | Takeda Pharmaceuticals North AmericaPosted: Feb 22
- San Francisco, CA | PwCPosted: Apr 12
Sponsored Financial Commentaries
To contact Angiogenix, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.